Transforming Outcomes in Head and Neck Cancer: Immunotherapy Takes Center Stage
WebcastFaculty
OVERVIEW
Transforming Outcomes in Head and Neck Cancer: Immunotherapy Takes Center Stage is organized by prIME Oncology and will be held during May 19, 2017 - May 19, 2018.
The target audience for this medical event is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer. This CME Conference has been approved for a maximum of 0.5 AMA PRA Category 1 Credits.
In this interactive, 30-minute activity, head and neck squamous cell cancer (HNSCC) experts discuss the rationale for targeting the immune system in HNSCC, the evidence for immune checkpoint inhibitors for recurrent and metastatic HNSCC, and the potential impact of biomarkers on response to immunotherapy. In addition, an actual patient with HNSCC provides insight on his experience from diagnosis through treatment with immunotherapy.
Topics:
• Why immunotherapy in head and neck cancer?
• Use of immune checkpoint inhibitors in HNSCC: What have we learned so far?
• Next steps for immunotherapy in head and neck cancer
• Patient perspective
• prIME Points
Conference Objectives are :
After successful completion of this educational activity, participants should be able to:
• Describe the rationale for targeting the immune system in HNSCC
• Evaluate efficacy and safety data of immune checkpoint inhibitors in recurrent and metastatic HNSCC and identify patients that may benefit from this treatment
• Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
• Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
• Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer. This CME Conference has been approved for a maximum of 0.5 AMA PRA Category 1 Credits.
In this interactive, 30-minute activity, head and neck squamous cell cancer (HNSCC) experts discuss the rationale for targeting the immune system in HNSCC, the evidence for immune checkpoint inhibitors for recurrent and metastatic HNSCC, and the potential impact of biomarkers on response to immunotherapy. In addition, an actual patient with HNSCC provides insight on his experience from diagnosis through treatment with immunotherapy.
Topics:
• Why immunotherapy in head and neck cancer?
• Use of immune checkpoint inhibitors in HNSCC: What have we learned so far?
• Next steps for immunotherapy in head and neck cancer
• Patient perspective
• prIME Points
Conference Objectives are :
After successful completion of this educational activity, participants should be able to:
• Describe the rationale for targeting the immune system in HNSCC
• Evaluate efficacy and safety data of immune checkpoint inhibitors in recurrent and metastatic HNSCC and identify patients that may benefit from this treatment
• Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
• Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
• Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer
Additional details will be posted as soon as they are available.
SPECIALITIES
OncologyImmunotherapies
Quick Links